Home
Search
Study Topics
Glossary
|
Study 16 of 37 for search of: | "Neurofibromatoses" |
Previous Study | Return to Search Results | Next Study |
|
|
|
|
|
Sponsored by: |
Children's Hospital of Philadelphia |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00060008 |
RATIONALE: New imaging procedures such as fludeoxyglucose F 18 positron emission tomography (FDG-PET) and magnetic resonance (MR) perfusion imaging may improve the ability to detect disease progression, help doctors predict a patient's response to treatment, and help plan the most effective treatment.
PURPOSE: This diagnostic trial is studying how well FDG-PET and MR perfusion imaging work in finding disease progression and determining response to treatment in patients with neurofibromatosis 1 and plexiform neurofibroma.
Condition | Intervention |
---|---|
Neurofibromatosis Type 1 (nf1) Precancerous/Nonmalignant Condition |
Drug: fludeoxyglucose F 18 Drug: gadopentetate dimeglumine Procedure: magnetic resonance imaging Procedure: positron emission tomography Procedure: radionuclide imaging |
Study Type: | Interventional |
Study Design: | Diagnostic, Open Label |
Official Title: | Novel Imaging Modalities For Plexiform Neurofibromas |
Estimated Enrollment: | 48 |
Study Start Date: | April 2002 |
Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
OBJECTIVES:
OUTLINE:
PROJECTED ACCRUAL: A total of 48 patients (32 for stratum 1 and 16 for stratum 2) will be accrued for this study.
Ages Eligible for Study: | up to 25 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Stratum 1:
At high risk for progression, as defined by any of the following:
Stratum 2:
Diagnosis of NF1 and progressive plexiform neurofibromas
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Stratum 1:
Stratum 2:
Endocrine therapy
Radiotherapy
Surgery
United States, Pennsylvania | |
Abramson Cancer Center of the University of Pennsylvania | Recruiting |
Philadelphia, Pennsylvania, United States, 19104-4283 | |
Contact: Clinical Trials Office - Abramson Cancer Center of the Univers 800-474-9892 | |
Children's Hospital of Philadelphia | Recruiting |
Philadelphia, Pennsylvania, United States, 19104 | |
Contact: Michael Fisher, MD 215-590-3129 |
Study Chair: | Michael Fisher, MD | Children's Hospital of Philadelphia |
Study ID Numbers: | CDR0000299006, CHP-724, CHP-IRB-2001-8-2543 |
Study First Received: | May 6, 2003 |
Last Updated: | December 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00060008 |
Health Authority: | Unspecified |
neurofibromatosis type 1 (NF1) plexiform neurofibroma |
Precancerous Conditions Neurodegenerative Diseases Neurofibromatosis type 1 Neurofibromatosis 1 Neoplastic Syndromes, Hereditary Heredodegenerative Disorders, Nervous System Genetic Diseases, Inborn Neurofibroma |
Neuromuscular Diseases Peripheral Nervous System Diseases Neurofibromatoses Peripheral Nervous System Neoplasms Neurofibroma, Plexiform Nerve Sheath Neoplasms Nervous System Neoplasms Neurocutaneous Syndromes |
Neoplasms Neoplasms by Histologic Type Nervous System Diseases Neoplasms, Nerve Tissue |